Merrill maintains Myriad at buy

Myriad Genetics Inc. was maintained at a buy by Merrill Lynch analyst David Munno, contrary to a New York Times article, based on a JAMA article, claiming that Myriad's test for breast cancer genes is flawed. Merrill does not expect any changes in the use of Myriad's predictive tests or its revenue estimates based on the JAMA and New York Times articles. Shares of the Salt Lake City biopharmaceutical company were down $1.56, or 5.72%, at $25.69 on volume of 2,813,374 shares versus the three-month running average of 362,738 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.